Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

Rhea-AI Summary

Oculis (NASDAQ:OCS) on March 27, 2026 announced annual equity incentive awards granted to a member of its executive committee.

The notification covers an executive equity award and accompanies an attached manager-transaction notice dated March 2026.

Key Figures

Registered resale shares: 494,259 ordinary shares Currently exercisable warrant: 59,310 shares Warrant exercise price: $12.17 +5 more

8 metrics

Registered resale shares 494,259 ordinary shares Maximum shares registered under Form F‑3 warrant resale

Currently exercisable warrant 59,310 shares Portion of warrant currently exercisable under F‑3

Warrant exercise price $12.17 Exercise price for 361,011 warrant shares

Warrant exercise price $18.64 Exercise price for 133,248 warrant shares

Max cash from warrant $6,877,246.59 Proceeds if all 494,259 warrant shares exercised for cash

Shares outstanding 52,374,811 shares Ordinary shares outstanding as of Sep 30, 2025

Underwritten offering size 4,691,358 shares Underwritten equity offering at $20.25 per share (Oct 31, 2025 424B5)

Registered direct sale 740,740 shares Registered direct equity sale at $20.25 per share (Oct 31, 2025 424B5)

Market Reality Check

Price: $24.69 Vol: Volume 125,531 vs 382,918...

low vol

$24.69 Last Close

Volume Volume 125,531 vs 382,918 20-day average (about 0.33x typical activity) ahead of this filing-focused news. low

Technical Price $24.69 is trading above the 200-day MA $21.13, indicating a pre-existing upward trend into this governance update.

Peers on Argus

OCS was roughly flat (-0.04%) while selected biotech peers like ABUS, EYPT, QURE...

1 Up

OCS was roughly flat (-0.04%) while selected biotech peers like ABUS, EYPT, QURE and TSHA showed mostly negative price changes, and momentum data flagged only TSHA on the upside. This points to stock-specific, routine disclosure rather than a broad sector move.

Historical Context

5 past events · Latest: Mar 16 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 16	Clinical data update	Positive	+1.6%	Phase 2 ACUITY results and Breakthrough Therapy status for Privosegtor.
Mar 16	Insider share purchase	Neutral	+1.6%	Board member ordinary share purchases disclosed via PDMR notification.
Mar 11	Equity awards granted	Neutral	-0.7%	Annual equity incentive awards for executive committee members disclosed.
Mar 06	RSU vesting notice	Neutral	+1.7%	Vesting and settlement of RSUs for multiple company directors reported.
Mar 05	Annual report filing	Neutral	+0.1%	Filing of 2025 audited IFRS financial statements and MD&A on Form 20‑F.

Pattern Detected

Recent Oculis headlines mix clinical progress, financings and recurring PDMR/compensation notices, with these governance items typically coinciding with modest, generally positive price reactions.

Recent Company History

Over the past month, Oculis has reported several governance-related disclosures and one major clinical presentation update. On Mar 5, 2026, it filed audited 2025 financial statements on Form 20‑F. Multiple March notices detailed RSU vesting and annual equity incentive awards for executives and directors, similar in nature to the current PDMR transaction disclosure. A Mar 16, 2026 clinical update on Privosegtor’s Phase 2 ACUITY results and Breakthrough Therapy status also supported the company’s longer-term development narrative.

Regulatory & Risk Context

Active S-3 Shelf · $6,877,246.59

Shelf Active

Active S-3 Shelf Registration 2025-11-10

$6,877,246.59 registered capacity

An effective Form F‑3 dated Nov 10, 2025 registers the resale of up to 494,259 ordinary shares issuable upon exercise of an existing warrant. Oculis is not selling shares under this prospectus; it would only receive up to $6,877,246.59 in cash if the warrant is fully exercised, so potential overhang comes from selling securityholder resales rather than new primary issuance.

Market Pulse Summary

This announcement reports annual equity incentive awards for a member of Oculis’s executive committe...

Analysis

This announcement reports annual equity incentive awards for a member of Oculis’s executive committee, consistent with a series of recent PDMR and RSU‑related disclosures in March 2026. It adds incremental detail on management compensation rather than changing the clinical or financial outlook. In the background, investors already have visibility on capital structure from the Form F‑3 registering 494,259 warrant‑linked shares and prior 424B5 equity offerings to fund pipeline development.

Key Terms

persons discharging managerial responsibilities, equity incentive awards

2 terms

persons discharging managerial responsibilities regulatory

"Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities"

Persons Discharging Managerial Responsibilities are the key people in a company who make big decisions, like top managers or executives. Knowing who they are is important because their actions can influence the company’s success or failure, and they are often required to share information about their dealings to ensure transparency for investors and the public.

equity incentive awards financial

"notification relates to annual equity incentive awards granted to a member"

Equity incentive awards are company grants that pay employees or directors with a stake in the business—typically stock, stock options, or restricted shares—rather than only cash. They matter to investors because they align employees’ interests with shareholders (like giving team members slices of the same pie to encourage growth) but can also increase the total number of shares outstanding, which can reduce each existing shareholder’s percentage ownership and impact reported profits.

AI-generated analysis. Not financial advice.

ZUG, Switzerland, March 27, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to annual equity incentive awards granted to a member of the executive committee of the Company.

Attachment

• notification-of-managers-transaction-riad-sherif-equity award-mar-2026

FAQ

What did Oculis (OCS) announce on March 27, 2026 about executive equity awards?

Oculis announced annual equity incentive awards granted to a member of its executive committee. According to the company, the announcement is a routine notification of manager transactions and includes an attached notice detailing the equity award date and recipient role.

Does the March 27, 2026 Oculis (OCS) notice indicate a stock sale or purchase by management?

The notice reports an equity incentive award rather than a market transaction like a sale or purchase. According to the company, the attached filing documents a grant of equity awards to an executive committee member, not a public trade order.

How should investors interpret the Oculis (OCS) March 27, 2026 equity award notification?

Investors should view this as a standard disclosure of management compensation through equity awards. According to the company, the filing notifies stakeholders of annual incentive grants and provides transparency about executive remuneration practices.

Will the Oculis (OCS) March 27, 2026 equity award notification cause immediate dilution for shareholders?

The notice does not specify immediate dilution or share issuance details in the summary provided. According to the company, the document is a notification of an award; specifics on issuance, vesting or dilution would appear in the attached transaction notice.

Where can investors find details of the March 27, 2026 Oculis (OCS) manager transaction notification?

Investors can review the attached notification that accompanies the announcement for full details. According to the company, the attachment named the manager transaction and contains the award specifics, date, and identity of the executive committee member.